Protara Therapeutics reports Q3 2021 net loss of $10.8M; FDA clears IND for TARA-002 in NMIBC

Protara Therapeutics, Inc.

2022-Q3 EPS reported -$3.30

Net loss $10.8M ($0.96/sh) vs $8.0M ($1.26/sh) in Q3 2020; R&D expense $4.1M (up from $2.8M), G&A $6.7M (up from $5.3M).
Cash, equivalents and marketable debt securities $138.4M as of Sept 30, 2021.
FDA cleared IND for TARA-002 in non-muscle invasive bladder cancer; Phase 1 trial start planned by year-end 2021.
Hired Mary Grendell (ex-Intercept Pharmaceuticals) as General Counsel; completed GMP comparability for TARA-002.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.